United States · Platforms & data · Zacks Investment Research

Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?

Published by Zacks Investment Research · United States 36 min ago

Read the full article on Zacks Investment Research Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (news.google.com)

Also worth reading

International Paper CEO Warns 2027 Will Be a ‘Slog’ as DS Smith Separation Advances

The Motley Fool

Did Anthropic's Valuation Drop by $900 Billion? Here's What Investors Should Know.

CoreWeave's strong results lift chip stocks; Micron leads Quant rankings

Anthropic’s IPO roadshow kicks off — and the big money is already lining up

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

GVS 9M 2026 slides: Q3 sales jump 13%, margins expand to 26%